Events - Biomea Fusion

Title: Combination Therapy of Icovamenib and Semaglutide Enhances Body Weight Loss and Glycemic Control While Preserving Lean Mass in a Type 2 Diabetes Animal Model

Supporting Materials

Combination Therapy of Icovamenib and Semaglutide Enhances Body Weight Loss and Glycemic Control While Preserving Lean Mass in a Type 2 Diabetes Animal Model 456.1 KB

85th Scientific Sessions of the American Diabetes Association (ADA) - Late Breaking Poster Presentation #1996-LB

Jun 22, 2025 at 12:30 PM CDT

Title: Icovamenib Rescues Human Myotube Atrophy Ex Vivo and Displays Complete Lean Mass Preservation in a Type 2 Diabetes Rat Model

Supporting Materials

Icovamenib Rescues Human Myotube Atrophy Ex Vivo and Displays Complete Lean Mass Preservation in a T2D Rat Model 1.4 MB

30th European Hematology Association (EHA) 2025 Congress

Jun 14, 2025

Supporting Materials

Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory (R/R) Acute Leukemia (AL): Preliminary Phase 1 Data from the COVALENT-103 Study (NCT05918692) 1.3 MB

Virtual Annual Meeting of Stockholders

Jun 11, 2025 at 10:00 AM PDT

Join Virtual Meeting

Discussing Icovamenib’s Disease Modifying Potential in Diabetes with KOL Steve Edelman MD: HCW KOL Call with Steve Edelman

Mar 27, 2025

Watch the vIdeo

18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) - Harnessing Menin Inhibition: Exploring Icovamenib as a Potential First-in-Class Medicine for Precision Diabetes Care

Mar 22, 2025 at 8:30 AM CET

Watch the video

Supporting Materials

Harnessing Menin Inhibition Exploring Icovamenib as a Potential First-in-Class Medicine for Precision Diabetes Care 6.5 MB

18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) - COVALENT-111: Evaluating Long-Term Efficacy and Safety of Short-Term Icovamenib Treatment in Persons with Type 2 Diabetes

Mar 21, 2025 at 10:35 AM CET

Supporting Materials

COVALENT-111: Evaluating Long-Term Efficacy and Safety of Short-Term Icovamenib Treatment in Persons With Type 2 Diabetes 652.2 KB

18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) - Combination of Icovamenib and GLP-1 Based Therapeutic Agents Improves Beta Cell Function and Insulin Secretion

Mar 20, 2025 at 4:10 PM EDT

Supporting Materials

Combination of Icovameniband GLP-1-Based Therapeutic Agents Improves Beta Cell Function and Insulin Secretion 716.7 KB

18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) - Exploring Icovamenib in Persons with Poorly Controlled Severe Insulin-Deficient (SIDD) Type 2 Diabetes

Mar 20, 2025 at 10:00 AM CET

Supporting Materials

COVALENT-111: Exploring Icovamenib in Persons With Poorly Controlled Severe Insulin-Deficient (SIDD) Type 2 Diabetes 618 KB

Discuss Menin Inhibitors for Diabetes with Ralph A. DeFronzo M.D.

Mar 19, 2025 at 1:00 PM EDT

Click here for webcast

Barclays 27th Annual Global Healthcare Conference

Mar 13, 2025 at 10:00 AM EDT

Click here for webcast

Oppenheimer 35th Annual Healthcare Life Sciences Conference

Feb 12, 2025 at 10:40 AM EST

Click here for webcast

43rd Annual J.P. Morgan Healthcare Conference

Jan 15, 2025 at 1:30 PM PST

Click here for webcast

Supporting Materials

J.P. Morgan Healthcare Conference Presentation 4.8 MB

COVALENT-111 Topline Results

Dec 17, 2024 at 8:00 AM EST

Click here for webcast

Supporting Materials

COVALENT-111 Topline Results Presentation 5.9 MB

22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Dec 12 - Dec 14, 2024

Supporting Materials

Investigating the Effects of Icovamenib on Poorly Managed Severe Insulin-Deficient Diabetes (SIDD): Insights from COVALENT-111 Case Studies Poster Presentation: December 12, 2024, at 6:30pm – 7:30pm PST 748.7 KB

Unlocking the Potential of Menin Inhibition: Icovamenib and a look into the Future of Diabetes Management Breakfast Symposium: December 13, 2024, at 7:00am – 7:45am PST 7.5 MB

Combination of Icovamenib and GLP-1-Based Therapeutic Agents Improves Beta Cell Function and Insulin Secretion Oral Presentation: December 13th, 2024, at 7:30pm – 9:00pm PST 1.6 MB

Biomea Update on COVALENT-103 Study of BMF-500 in Acute Leukemia

Dec 9, 2024 at 4:30 PM EST

Click here for webcast

Supporting Materials

Conference Call Presentation 1.4 MB

Biomea Fireside Chat at Evercore 7th Annual HealthCONx Conference

Dec 5, 2024 from 7:55 AM to 8:15 AM EST

Click here for webcast

Biomea Fireside Chat at Piper Sandler 36th Annual Healthcare Conference

Dec 3, 2024 from 10:00 AM to 10:25 AM EST

Click here for webcast

1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

Nov 18 - Nov 20, 2024

Supporting Materials

Trial in Progress COVALENT-111: A Phase 2 Trial of the Oral Menin Inhibitor Icovamenib (BMF-219) in Patients with Type 2 Diabetes (Oral Presentation: November 19 at 12:45 – 12:50 SGT) 216.2 KB

Late-Breaker: Assessment of Icovamenib (BMF-219) in Persons with Poorly Controlled Severe Insulin-Deficient (SIDD) Type 2 Diabetes (T2D): COVALENT-111 Case Studies (Oral Presentation: November 19 at 12:50 – 12:55 SGT) 615.2 KB

Unlocking the Potential of Menin Inhibition: Icovamenib and a Look into the Future of Diabetes Management (Industry Symposium: November 19 at 17:10 – 18:10 SGT) 7.1 MB

Watch the replay

Trial in Progress COVALENT-112: A Phase 2 Trial of the Oral Menin Inhibitor Icovamenib (BMF-219) in Type 1 Diabetes (Oral Presentation: November 20 at 11:25 - 11:35 SGT) 1.9 MB

Biomea Announces Lead Clinical GLP-1 RA Candidate, BMF-650, and Preclinical Combination Data

Oct 30, 2024 at 4:30 PM EDT

Click here for webcast

Supporting Materials

Biomea Announces Lead Clinical GLP-1 RA Candidate, BMF-650, and Preclinical Combination Data Presentation 2.9 MB

Transcript - Biomea Announces Lead Clinical GLP-1 RA Candidate, BMF-650, and Preclinical Combination Data 309.6 KB

Investor Conference Call and Webcast to Discuss FDA Clinical Hold Lift on BMF-219 in Type 2 and Type 1 Diabetes Trials

Sep 26, 2024 at 4:30 PM EDT

Click here for webcast

Innovation on the Island Biotech Summit

Apr 10 - Apr 11, 2024

Supporting Materials

Innovation on the Island Biotech Summit Presentation 1.4 MB

Barclays 26th Annual Global Healthcare Conference

Mar 14, 2024 at 12:15 PM EDT

Click here for webcast

17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Mar 6 - Mar 9, 2024

Supporting Materials

Durable Glycemic Control with BMF-219 during Off-Treatment Period at Week 26: A Phase 1/2 Trial of BMF-219 in Patients with Type 2 Diabetes (COVALENT-111) (Poster Discussion Session, March 7th, 10-10:30 am CET.) 407.9 KB

Listen to the MP3 recording

Key Observations from the Dose Escalation Portion of COVALENT-111, a Phase 1/2 Trial of the Covalent Menin Inhibitor BMF-219 in Patients with Type 2 Diabetes (Poster Viewing Session) 428 KB

Listen to the MP3 recording

Case Studies from COVALENT-111, A Phase 1/2 Trial of BMF-219, a Covalent Menin Inhibitor, in Patients with Type 2 Diabetes (Poster Viewing Session) 446.3 KB

Listen to the MP3 recording

42nd Annual J.P. Morgan Healthcare Conference

Jan 9, 2024 at 8:15 AM PST

Supporting Materials

Transcript for 42nd Annual J.P. Morgan Healthcare Conference 227.1 KB

Download the MP3 recording 18.4 MB

Biomea Poster Presentations at the 65th ASH

Dec 9 - Dec 10, 2023

Supporting Materials

ASH 2023 Poster on COVALENT-101 2.4 MB

ASH 2023 TIP Poster on COVALENT-103 1 MB

BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" at WCIRDC

Dec 8, 2023 at 7:30 PM PST

Oral Presentation

Supporting Materials

WCIRDC Abstract Oral Presentation 2.1 MB

WCIRDC 2023 Poster 1.3 MB

BMF-219: An oral menin inhibitor in clinical development as a short-term treatment to address the root cause of diabetes, beta-cell dysfunction” at the 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Dec 7, 2023 at 7:00 AM PST

Breakfast Educational Session

Watch the replay

Supporting Materials

WCIRDC Breakfast Symposium Presentation 6.9 MB

Biomea Fireside Chat with Evercore ISI

Nov 30, 2023 at 8:45 AM EST

Click here for webcast

Supporting Materials

Transcript for Biomea Fireside Chat with Evercore ISI 130.8 KB

Biomea Fireside Chat with Piper

Nov 29, 2023 at 2:00 PM EST

Click here for webcast

Supporting Materials

Transcript for Biomea Fireside Chat with Piper 153.8 KB

Biomea Fireside Chat with Wells Fargo

Sep 7, 2023 at 9:30 AM EDT

Click here for webcast

Supporting Materials

Transcript for Biomea Fireside Chat with Wells Fargo 164.4 KB

Biomea Virtual Fireside Chat with Barclays

Jun 28, 2023 at 12:00 PM EDT

Click here for webcast

Supporting Materials

Transcript for Biomea Virtual Fireside Chat with Barclays 641.7 KB

Investor Conference Call and Webcast to Discuss Biomea Fusion’s ADA 2023 Scientific Sessions Presentation in San Diego

Jun 26, 2023 at 8:30 AM EDT

Click here for webcast

Supporting Materials

COVALENT-111 ADA 2023 Data Update 1.8 MB

COVALENT-111: PHASE II - Preliminary Results of Healthy Volunteer (HV) and Type 2 Diabetes Mellitus (T2DM) 100mg Cohorts 4.3 MB

Transcript 187.5 KB

The American Diabetes Association (ADA) featured Biomea during its yearly “Thought Leadership Film Series” of innovative therapies at its 83rd Annual Meeting

Jun 23, 2023

Watch the video

H.C. Wainwright BioConnect Investor Conference at NASDAQ

May 2, 2023 at 6:00 AM EDT

Click here for webcast

Conference Call and Webcast to Discuss Clinical Data From the First Two Cohorts of BMF-219 in Patients With Type 2 Diabetes

Mar 28, 2023 at 8:30 AM EDT

Click here for webcast

Supporting Materials

Conference Call Presentation 2.3 MB

Transcript for Conference Call to Discuss Clinical Data From the First Two Cohorts of BMF-219 in Patients With Type 2 Diabetes 175.6 KB

Oppenheimer’s 33rd Annual Healthcare Conference

Mar 15, 2023 at 11:20 AM EDT

1x1 Virtual Meetings on Monday, March 13, 2023

Barclays Global Healthcare Conference

Mar 14, 2023 at 4:35 PM EDT

Virtual Fireside Chat with Oppenheimer & Co.: Type 2 Diabetes and New Treatment Options with Biomea Fusion (BMEA) Mgmt. & Key Opinion Leaders

Mar 2, 2023 at 12:00 PM EST

Guggenheim Oncology Conference 2023

Feb 8, 2023 at 2:45 PM EST

Format: Fireside chat

Speaker: Steve Morris M.D., Biomea Fusion Chief Medical Officer

Watch the replay

Supporting Materials

Guggenheim Oncology Conference 2023 Fireside Chat Summary 241.4 KB

J.P. Morgan 41st Annual Healthcare Conference

Jan 11, 2023 at 8:15 AM PST

Click here for webcast

Supporting Materials

J.P. Morgan 41st Annual Healthcare Conference Presentation 7.6 MB

FDA Clearance of IND for BMF-219 in Type 2 Diabetes

Dec 15, 2022 at 4:00 PM EST

Those who plan on participating in the Q&A may register here to receive dials and a unique PIN to join the call. Otherwise please listen via the webcast.

Click here for webcast

Supporting Materials

FDA Clearance of IND for BMF-219 in Type 2 Diabetes Presentation 1.5 MB

FDA Clearance of IND for BMF-219 in Type 2 Diabetes Transcript 348.3 KB

Piper Sandler 34th Annual Healthcare Conference

Nov 29, 2022 at 3:30 PM EST

Jefferies Healthcare Conference

Jun 8, 2022 at 2:30 PM EDT

Format: Fireside chat

Click here for webcast

Supporting Materials

Jefferies Healthcare Conference Transcript 170 KB

Covalent Menin Inhibitor BMF-219’s Activity in Diabetes as presented at the 82nd American Diabetes Association Annual Conference

Jun 6, 2022 at 1:05 PM PDT

Click here for webcast

Supporting Materials

ADA TV - Film Highlights 226.5 KB

82nd American Diabetes Association Conference Call Presentation 1.9 MB

Biomea Fusion ADA 2022 Video

H.C. Wainwright Global Investment Conference

May 23 - May 27, 2022

Bank of America Securities 2022 Healthcare Conference

May 11, 2022 at 4:00 PM PDT

Click here for webcast

Irreversible menin inhibitor, BMF-219, inhibits the growth of KRAS-mutated solid tumors (Abstract #1202)

Apr 12, 2022 from 9:00 AM to 12:30 PM CDT

Session Category: Experimental and Molecular Therapeutics
Session Title: Signaling Pathway Inhibitors
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 25
Poster Board Number: 8
Permanent Abstract Number: 2665

Anti-tumor activity of irreversible menin inhibitor, BMF-219, in high-grade B-cell lymphoma and multiple myeloma preclinical models (Abstract #1205)

Apr 12, 2022 from 9:00 AM to 12:30 PM CDT

Session Category: Experimental and Molecular Therapeutics
Session Title: Novel Targets and Pathways
Location: New Orleans Convention Center, Exhibit Halls D-H, Poster Section 24
Poster Board Number: 23
Permanent Abstract Number: 2654

Oppenheimer 32nd Annual Virtual Healthcare Conference

Mar 16, 2022 at 7:00 AM PDT

Click here for webcast

40th Annual J.P. Morgan Healthcare Conference

Jan 12, 2022 at 3:00 PM EST

Click here for webcast

Supporting Materials

Transcript 3.1 MB

H.C. Wainwright BioConnect Conference

Jan 10 - Jan 13, 2022

Click here for webcast

Supporting Materials